JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms-Reference-Cited by-同舟云学术

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

Published:2015-03-30 Issue:6 Volume:169 Page:824-833
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Parampalli Yajnanarayana Sowmya¹,Stübig Thomas²,Cornez Isabelle¹,Alchalby Haefaa²,Schönberg Kathrin¹,Rudolph Janna¹,Triviai Ioanna²,Wolschke Christine²,Heine Annkristin¹,Brossart Peter¹,Kröger Nicolaus²,Wolf Dominik¹

Affiliation:

1. Department of Internal Medicine III, Oncology, Haematology and Rheumatology; University Hospital Bonn (UKB); Bonn Germany

2. Department of Stem Cell Transplantation; University Medical Centre Hamburg; Hamburg Germany

Funder

Deutsche Forschungsgemeinschaft

BONFOR

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13373/fullpdf

Reference32 articles.

1. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells;Afkarian;Nature Immunology,2002

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells;Burchill;Journal of Immunology (Baltimore, Md.: 1950),2007

4. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis;Cervantes;Blood,2013

5. EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry;Cornez;Journal of Neuro-Oncology,2013

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy;Frontiers in Immunology;2024-08-30

2. CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1;Cell Death Discovery;2024-08-29

3. FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN);Annals of Hematology;2024-07-05

4. Targeting exhausted cytotoxic T cells through CTLA‐4 inhibition promotes elimination of neoplastic cells in human myelofibrosis xenografts;American Journal of Hematology;2024-07-02

5. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma;Science;2024-06-21